1   **A Genetic Screen in *Drosophila* uncovers a role for *senseless-2* in surface glia in the**

2   **peripheral nervous system to regulate CNS morphology**

7   **Haluk Lacin[1][#], Yuqing Zhu[2][#], Jose T. DiPaola[2][#], Beth A. Wilson[2], Yi Zhu[2], James B. Skeath[2]***

12   [1]Division of Biological and Biomedical Systems, University of Missouri-Kansas City, Kansas
13   City, MO 64110, USA
14
15   [2]Department of Genetics, Washington University School of Medicine, 4523 Clayton Avenue, St.
16   Louis, MO 63110, USA
17
18
19

20   Keywords: Drosophila, *senseless-2*, *papilin*, CNS, glia, basement membrane
21

28   *Corresponding Author: jskeath@wustl.edu

29   [#]These authors contributed equally to the article

Abstract: Despite increasing in mass approximately 100-fold during larval life, the *Drosophila* CNS maintains its characteristic form during this rapid growth phase. Dynamic interactions between the overlying basement membrane and underlying surface glia are known to regulate CNS structure in *Drosophila*, but the genes and pathways that establish and maintain CNS morphology during development remain poorly characterized. To identify genes that regulate CNS shape in *Drosophila*, we conducted an EMS-based, forward genetic screen of the second chromosome, uncovered 50 mutations that disrupt CNS structure, and mapped these alleles to 17 genes. Whole genome sequencing revealed the affected gene for all but one mutation. Identified genes include well characterized regulators of tissue shape, like *LanB1, viking, and Collagen type IV alpha1*, as well as previously characterized genes, such as *Toll-2* and *Rme-8*, with no known role in regulating CNS structure. We also uncovered that *papilin* and *C1GalTA* likely act in the same pathway to regulate CNS structure and found that the fly homolog of a glucuronosyltransferase, B4GAT1/LARGE1, that regulates Dystroglycan function in mammals is required to maintain CNS shape in *Drosophila*. Finally, we show that the *senseless-2* transcription factor is expressed and functions specifically in surface glia found on peripheral nerves but not those on the CNS proper to govern CNS structure, identifying a gene that functionally subdivides a glial subtype along the peripheral-central axis. Future work on these genes should clarify the genetic mechanisms that ensure the homeostasis of CNS shape and form during development.

Introduction:

Structure determines function is a unifying theme of biology. A thorough understanding of the genes that govern tissue or organ structure is, however, lacking. We use the *Drosophila* larval CNS as a model system to investigate the genetic factors that control tissue shape (Skeath, Wilson et al. 2017). The *Drosophila* larval CNS adopts its distinctive shape at the end of embryogenesis upon the shortening and thickening of the nerve cord in response to the concerted action of hemocytes, neural activity, and glial cell function in a process called nerve cord condensation (Olofsson and Page 2005, Karkali, Tiwari et al. 2022). Once its shape is established, the *Drosophila* CNS maintains its form throughout its massive growth during larval development.

The *Drosophila* larval CNS is consecutively and fully enwrapped by the CNS basement membrane and the perineurial and subperineurial surface glial cells, with the surface glia functioning as the blood-brain-barrier (Stork, Engelen et al. 2008, Meyer, Schmidt and Klambt 2014, Yildirim, Petri et al. 2019). The basement membrane is composed of independent Collagen IV and Laminin networks that are connected to each other by Perlecan; both networks establish connections to surface glial cells through interactions with the Integrin and Dystroglycan cell surface receptors (Yurchenco 2011). The tethering of the basement membrane to surface glial cells provides the CNS with structural and biomechanical strength essential to maintain its distinct shape. Interactions between the basement membrane and surface glia are, however, far from static. The tremendous growth of the CNS during larval life demands a dynamic basement membrane-surface glia interface that imparts structure to the CNS, while being continually remodeled to allow tissue growth and expansion.

In the larvae, the fat body secretes basement membrane proteins that are continuously deposited on the CNS basement membrane during development (Pastor-Pareja and Xu 2011), coordinating

basement membrane deposition with tissue growth in the CNS. Remodeling of the basement

membrane occurs at least in part through the action of the membrane-tethered and secreted

extracellular proteases MMP1, MMP2, and AdamTS-A, which are expressed by surface glia

(Page-McCaw, Serano et al. 2003, Meyer, Schmidt and Klambt 2014, Skeath, Wilson et al. 2017).

These proteases oppose the tissue stiffening action of Collagen IV by cleaving basement

membrane proteins and in so doing help maintain a delicate balance between tissue stiffness and

softness that maintains tissue structure while allowing tissue growth and expansion (Apte 2009,

Miller, Liu et al. 2011, Rodriguez-Manzaneque, Fernandez-Rodriguez et al. 2015, Skeath, Wilson

et al. 2017). In addition to the fat body, migratory hemocytes also express basement membrane

proteins in larvae and may serve as a second source of basement membrane proteins and a

remodeling agent for the basement membrane (Isabella and Horne-Badovinac 2015).

To gain more insight into the factors that regulate CNS shape, we undertook a large-scale forward

genetic screen of the second chromosome to identify mutations that disrupt CNS structure. Our

screen identified 17 genes, including characterized regulators of tissue structure, characterized

genes with no known role in controlling tissue structure, such as *Toll-2* (*18-wheeler*) *and Rme-8*,

and previously uncharacterized genes, like a glucuronosyltransferase homologous to B4GAT1

and LARGE1/2, which regulate Dystroglycan in mammals, and the transcription factor Senseless-

2. Our results highlight an unexpected role for perineurial glia in the peripheral nervous system

(PNS) to help to establish and maintain CNS structure.

Results and Discussion

The cellular and molecular processes that control CNS shape are poorly understood. To gain

insight into these processes, we performed a large-scale EMS-based, forward genetic screen of

the second chromosome to identify mutations that disrupt the morphology of the larval CNS (Fig.

1). Briefly, we used a target chromosome that contains a *3xP3-RFP* transgene insert in the second

chromosome that labels most glia (Zhu, Cho et al. 2024), enabling rapid visualization of the CNS

in live larvae. We set up 17,790 single male F1 crosses, screened 12,211 F3 lines for second

chromosomal mutations that when homozygous were larval-, pupal-, or semi-lethal, identified

3180 such lines, and visually screened each for defects in overall CNS morphology. We identified

50 mutations that disrupt CNS shape, including 11 mutations in *LanB1*, *viking* or *Col4a1,* genes

which have well characterized roles in regulating tissue and CNS structure (Pastor-Pareja and Xu

2011, Kim, Jeibmann et al. 2014, Skeath, Wilson et al. 2017, Dai, Estrada et al. 2018). The 39

remaining mutations grouped into three phenotypic classes: those with a wider CNS (n=1), a

herniated or misshapen CNS (n=15), and an elongated CNS (n=23). Complementation crosses

identified eight complementation groups and six "singleton" mutations among these 39 lines, and

whole genome sequencing of most lines at $\geq$30X coverage identified the causative lesion(s) in

and affected gene for 13 of the 14 genes. When possible, phenotypic analysis with appropriate

deficiencies and gene-specific alleles was used to confirm correspondence between gene and

mutant phenotype for the 13 genes. The CNS phenotype, molecular nature, and known function

of these genes are summarized in Table 1 and Figure 2.

Below, we outline the genes identified in the screen and their associated mutations and CNS

phenotypes, starting with the gene/mutation that yielded a wider CNS and ending with those that

yielded an elongated CNS. We describe in greater detail the function of the *senseless-2* gene,

which encodes a Zinc finger transcription factor that may act as a genetic switch to distinguish

perineurial glial found in the PNS from those in the CNS.

<u>Gene that yields a widened CNS phenotype when mutated</u>

diaphanous: We identified one mutant allele that when homozygous yielded a wider CNS. This

allele identified a frameshift mutation found immediately after the codon for amino acid 51 in the

diaphanous coding region and resulted in an expansion of the thoracic region of the CNS that

became more pronounced as larvae were about to pupariate (Table 1; Figs. 2, 3). *diaphanous*

encodes the sole Dia-class formin protein in *Drosophila*; it is required for cytokinesis and induces

polyploidy in follicle cells and mitotic neuroblasts (Castrillon and Wasserman 1994). Using

antibodies specific to Deadpan and ELAV to label neuroblasts and neurons, respectively, we

observed a massive increase in neuroblast size likely caused by defects in cytokinesis and

increased ploidy of these cells (Fig. 3). Our results indicate that the expanded nature of the

thoracic ventral nerve cord in *diaphanous* mutants likely results from the expanded size of

neuroblasts and potentially other cell-types in the CNS.

Genes that yield a misshapen CNS phenotype when mutated

We identified mutations in three genes – *Dark, Toll-2*, and one singleton mutation – that gave rise

to a misshapen CNS (Table 1). We identified 11 alleles of *Dark*. Homozygosity or trans-

heterozygosity for each allele yielded a mild, partially penetrant CNS phenotype in which small

hernias arise in the CNS (Fig. 2). We sequenced three of the identified alleles, each of which

contained an apparently identical 370-bp deletion within the coding region (Table 1). The identity

of the molecular lesions in these alleles suggest the mutations arose in mitotic spermatagonia or

spermatocyte cells and are not independent of each other. *Dark* encodes a homolog of the Apaf-

1/Ced-4 pro-apoptotic genes and has been shown to promote hyperplasia in the CNS (Rodriguez,

Oliver et al. 1999).

Toll-2: Three allelic mutations identified the *Toll-2* (*18-wheeler*) gene with two of the mutations

being premature stop codons and the third being a missense mutation in the leucine-rich repeat

domain (Table 1; Fig. 4). Loss of *Toll-2* function reduced CNS size and resulted in a misshapen

ventral nerved cord marked by irregularly shaped protrusions, hernias, and indentations (Fig. 2

and 4). The CNS phenotype of the *Toll-2* mutants grossly resembles that of *perlecan*, which

encodes one of the key components of the CNS basement membrane (Yurchenco 2011), hinting

that Toll-2 receptors may function in surface glia to regulate CNS morphology by interfacing with

components of the basement membrane. Cell death may also contribute to the observed defects

in CNS morphology, as loss of *Toll-2* function has been shown to drive cell death in neurons and

neuroblasts (Li, Forero et al. 2020, Hermanstyne, Johnson et al. 2022),.

The *jsZ4* allele represents the sole mutation that we were unable to map to a defined gene (Table

1). Its partially penetrant phenotype is highlighted by an elongated nerve cord and the presence

of hernias and protrusions in it (Fig. 2). As we sequenced the genome of this allele at $\geq$30X

coverage, our failure to map its mutant phenotype to a specific gene could arise due to the

phenotype being caused by two or more mutations, a non-coding mutation, or other reasons.

Genes that yield an elongated CNS phenotype when mutated

Our largest phenotypic class – an elongated CNS – was identified by 23 mutations and 9 genes.

Two of the 9 genes are known tumor suppressors – *lethal giant larvae* (*lgl*) and *brain tumor* (*brat*).

We identified a single mutation in *lgl*, a frame-shift mutation which when homozygous yields an

elongated ventral nerve cord and greatly enlarged brain lobes (Table 1, Fig. 2). Complementation

crosses against the *lgl*[4] allele and a deficiency that uncovers *lgl* confirmed correspondence

between the gene and mutant phenotype. The elongated CNS phenotype likely arises from

elevated cell proliferation since *lgl* plays a well characterized role in restricting cell proliferation

(Gateff and Schneiderman 1974). Like *lgl*, loss of *brat* function is known to increase neuroblast

and cell proliferation and result in tumorous growths in the brain (Gateff 1994). We identified three

mutations in *brat* that yielded a moderate CNS elongation phenotype (Table 1, Fig. 2).

worniu: We identified a nonsense mutation, L117*, in *worniu* that yielded a moderately elongated

nerve cord (Table 1; Fig. 2). We confirmed correspondence between *worniu* and the mutant

phenotype based on the new *worniu*[js1] allele failing to complement both the *worniu*[1] and *worniu*[2]

alleles for the elongated nerve cord phenotype. *worniu* encodes a C2H2-type Zinc finger

transcription factor that is expressed in most neuroblasts and has been shown to regulate CNS

structure (Ashraf, Ganguly et al. 2004).

Tango1: We identified a missense mutation, T60I, in the *Tango1* coding region that when

homozygous resulted in a moderately elongated CNS (Table 1; Fig. 2). We confirmed

correspondence between this mutation and the observed CNS elongation phenotype by

complementation against two overlapping deficiencies that each uncover *Tango1*. *Tango1*

functions at ER exit sites to promote protein secretion and is required to promote the specialized

secretion of the large Collagen and Laminin proteins (Saito, Chen et al. 2009, Malhotra and

Erlmann 2011, Wilson, Phamluong et al. 2011, Petley-Ragan, Ardiel et al. 2016). Thus, the CNS

elongation phenotype of *Tango1* likely derives from defective secretion and deposition of

basement membrane proteins, as loss of function in the basement membrane proteins, such as

LanB1, *vkg*, and *Col4a1* lead to an elongated CNS (Pastor-Pareja and Xu 2011, Kim, Jeibmann

et al. 2014, Skeath, Wilson et al. 2017, Dai, Estrada et al. 2018).

Rme-8: Three mutations in the *Rme-8* gene also gave rise to a moderately elongated CNS

phenotype when homozygous or trans-heterozygous to each other (Table 1; Fig. 1, 5). Rme-8

encodes a DnaJ domain-containing protein of the Hsp40 chaperone family that also contains four

IWN repeat (Zhang, Grant and Hirsh 2001, Norris, McManus et al. 2022); Rme-8 promotes

endocytic recycling of transmembrane proteins, such as Notch (Gomez-Lamarca, Snowdon et al.

2015). Using an *Rme-8-T2A-GAL4* CRIMIC insert in the fourth intron of *Rme-8* to drive a UAS-

linked nuclear-RFP transgene (Lee, Zirin et al. 2018, He, Binari et al. 2019), we found that Rme-

8 is broadly expressed in the CNS in neurons and glia, especially surface glia (data not shown).

The remaining five genes (*Pvf3, CG9171, C1GalTA, ifc,* and *sens-2*) all exhibited severe CNS

elongation phenotypes upon loss of their function.

Pvf3: We identified a single mutation in *Pvf3* – a splice site donor mutation just prior to the region

that encodes its PDGF domain (Table 1; Fig. 2, 6). Larvae homozygous for this mutation yield a

highly elongated CNS, which is recapitulated when this allele is placed in trans to the *Df(2L)ΔPvf2-*

3 deficiency or two P element inserts in *Pvf3* (see Methods; (Parsons and Foley 2013)), confirming

correspondence between *Pvf3* and the elongated CNS phenotype. *Pvf3* acts together with *Pvf2*

to promote hemocyte survival and migration through activation of the Pvr receptor (Parsons and

Foley 2013). Loss of Pvr function or blockade of its neural activity has been shown to inhibit nerve

cord condensation and promote nerve cord elongation (Olofsson and Page 2005). Our

observation that loss of *Pvf3* function alone yields a highly elongated CNS phenotype suggests

that *Pvf3* plays a non-redundant role relative to *Pvf2* to promote hemocyte survival, migration,

and/or function.

CG9171: Four mutant alleles identified *CG9171*, which encodes a predicted

glucuronosyltransferase that promotes O-linked protein mannosylation. All four mutations reside

in its extracellular glycosyl-transferase domain, likely disrupting enzymatic function (Fig. 7).

Homozygous or trans-heterozygous mutants of all four mutations yield a highly elongated CNS

phenotype, but neuroblast formation and neuronal patterning appear grossly normal (Fig. 7). The

most closely related mammalian homologs of *CG9171* – *B4GAT1* and *LARGE1/2* – act in tandem

to drive the O-mannosylation of Dystroglycan (Praissman, Live et al. 2014). B4GAT1 adds a

single glucuronic acid residue onto a Xylose acceptor on Dystroglycan. The related

glycosyltransferase LARGE recognizes this epitope and extends it by adding many copies of a

repeating disaccharide to form matriglycan. Matriglycan links Dystroglycan to the basement

membrane by binding to Laminin and other proteins and plays a key role in disease, as mutations

in B4GAT1 in humans cause dystroglycanopathies likely due to the loss of matriglycan on Dystroglycan (Yoshida-Moriguchi, Yu et al. 2010, Praissman, Live et al. 2014, Bigotti and Brancaccio 2021). Our work suggests that defects in the O-mannosylation of Dystroglycan and/or other cell surface proteins cause the observed CNS elongation phenotype.

C1GalTA: Like *CG9171*, the two alleles in *Core 1 Galactosyltransferase A* (*C1GalTA; CG9520*) yielded a highly elongated CNS phenotype (Table 1; Fig. 2). Unlike the CG9171 phenotype in which the mutant ventral nerve cord is supple and flexible, *C1GalTA* mutant larvae exhibited a highly elongated, very brittle nerve cord, flat and misshapen brain lobes, reduced fat body tissue integrity, and direct adherence of portions of the fat body to the CNS (Fig. 8; data not shown). These phenotypes are most obvious in larvae homozygous for the phenotypically stronger *C1GalTA^{js1}* allele. C1GalTA promotes protein glycosylation by adding galactose in a β1,3 linkage to N-acetylgalactosamine (GalNAc) on proteins. In flies, a prior study showed that *dC1GalTA* is required for glycosylation of Laminin and the presence of T antigen (Gal β1,3 GalNAc) on hemocytes, and that loss of *C1GalTA* function drives CNS elongation (Lin, Reddy and Irvine 2008).

The *C1GalTA* mutant phenotype resembles that of *papilin* (*ppn*), a third chromosomal gene that we were working on in parallel to the genetic screen due to its sequence similarity to AdamTS genes (Campbell, Fessler et al. 1987, Kramerova, Kawaguchi et al. 2000, Keeley, Hastie et al. 2020). Ppn is a key component of the basement membrane, where it has been shown to facilitate Collagen IV removal to promote basement membrane remodeling (Keeley et al., 2020). Like the *C1GalTA* mutant phenotype, reduction of *ppn* function yields a highly elongated and brittle nerve cord, flat and misshapen brain lobes, reduced fat body integrity, and portions of the fat body adhering to the CNS (Fig. 9, data not shown). A *ppn*-T2A-GAL4 reporter and Ppn-specific antibodies showed that *ppn* is transcribed in hemocytes, the cells that assemble and disassemble

basement membranes, but not in most other tissues (Fig. 9; data not shown), including the fat

body – the major producer of basement membrane proteins in larvae (Pastor-Pareja and Xu

2011). Ppn protein, however, is found on the basement membrane of most tissues (not shown).

We hypothesize that hemocytes deposit Ppn on most tissues during development.

Most basement membrane components, like Col4a1, Vkg, Nidogen, and Perlecan, are produced

by fat body cells (Pastor-Pareja and Xu 2011), but Ppn is not expressed in the fat body, suggesting

there may be a physiological reason for exclusion of Ppn transcription in the fat body. To test this

model, we misexpressed *ppn* in the fat body and asked if it altered basement membrane protein

localization by visualizing the localization of a GFP protein trap in Viking (Morin, Daneman et al.

2001). Upon forced *ppn* expression in the fat body, we observed a massive, cell autonomous

retention of Viking-GFP in fat body cells (Fig. 9), demonstrating incompatibility of fat body *ppn*

expression with appropriate Viking secretion and suggesting that Ppn physically associates with

Viking in vivo to help mediate the removal of the basement membrane components. The similarity

of the *ppn* and *C1GalTA* mutant phenotypes suggests that C1GalTA acts with Ppn to promote

Viking/Collagen IV removal from the basement membrane and that failure to do so results in a

brittle, elongated CNS. Future work that determines how these genes functionally interface with

each other should help clarify the molecular basis of basement membrane remodeling and the

control of tissue structure.

infertile crescent: Three alleles identified *infertile crescent (ifc)*, which encodes the sole *Drosophila*

dihydroceramide desaturase that converts dihydroceramide to ceramide in the de novo ceramide

biosynthesis pathway (Jung, Liu et al. 2017) (Hannun and Obeid 2018). Loss of *ifc* results in an

elongated CNS marked by bulges in peripheral nerves (Fig. 2); we characterized the function of

ifc in detail in a separate study and found it primarily functions in glia to promote glial homeostasis

and to protect against neuronal death and neuronal degeneration (Zhu, Cho et al. 2024).

Senseless-2 acts in perineurial glia to regulate CNS structure

Four mutant alleles identified the *senseless-2* (*sens-2*) gene, which encodes a member of the

Zinc finger C2H2 superfamily of proteins and possesses six C2H2 Zinc finger domains (Fig. 2,

10A). Three of the alleles – *sens-2^{js2}, sens-2^{js3},* and *sens-2^{js4}* – introduce, respectively, an early

splice site mutation, a missense mutation in a conserved cysteine in the Zinc finger domain, and

an early frame-shift mutation (Table 1). These alleles yield an essentially identical highly

elongated CNS phenotype (Fig. 10B, 10C) and are then likely null or strong hypomorphic alleles.

The fourth allele, *sens-2^{js1}*, yields a modest CNS elongation phenotype; larvae trans-

heterozygous for *sens-2^{js1}* and *sens-2^{js4}* exhibit an intermediate CNS elongation phenotype

between the two alleles, identifying *sens-2^{js1}*, which contains a missense mutation in the zinc

finger domain (Table 1), as a weak hypomorphic allele of *sens-2*.

The *sens-2* CNS elongation phenotype manifests in first instar larvae and is maintained

throughout larval life and into pupal stage at which point *sens-2* homozygous flies die. In live third

instar larvae, the CNS appears to be under tension from both laterally and posteriorly projecting

peripheral nerves, with the posterior nerves being shorter in length in *sens-2* mutant larvae

relative to wild-type (Fig. 2, 10A). The overall shape of the CNS is dramatically altered, but the

overall pattern of neuroblasts and neurons appeared grossly wild-type with no significant change

in neuroblast number (Fig. 10A).

To clarify the cellular basis for the *sens-2* CNS elongation phenotype, we tracked *sens-2*

expression in larvae by generating a Sens-2 specific antibody and a *sens-2-T2A-GAL4* CRIMIC

line ("*sens-2-GAL4*") and leveraging a *sens-2-GFP* transgene surrounded by its endogenous

genomic locus ((Kudron, Victorsen et al. 2018); see Methods). These tools revealed that *sens-2*

is expressed in subsets of glia and neurons in the larval nervous system (Figs. 10C-F, S1-3) and

in a region-specific manner in the gut (not shown). We focused on *sens-2* expression in the

nervous system, as its function in glia, neurons, or both likely contributes to the observed CNS

phenotype. Double-labeling experiments with REPO to mark all glia and ELAV to label all neurons

revealed that *sens-2* is expressed in a small number of CNS neurons and most glia in peripheral

nerves, but that *sens-2* is not detected in any glia within the CNS itself (Figs. 10D-E, S2, S3).

More detailed analysis of *sens-2* expression within peripheral nerves of late third instar larvae

suggested that *sens-2* is expressed in all perineurial glia and weakly in some subperineural glia,

but that its expression appears to be excluded from wrapping glia and most subperineurial glia

(Figs. 10F, S2, S3). We conclude that *sens-2* expression demarcates PNS perineurial glia (*sens-*

2-positive) from CNS perineurial glia (*sens-2*-negative), identifying *sens-2* as one of the first

markers to distinguish a glial subtype along the CNS-PNS axis.

12
13
To determine if *sens-2* function is required in glia, neurons or both to regulate CNS structure, we

used the GAL4/UAS system together with either a *UAS-sens-2-RNAi* transgene or a *UAS-sens-*

2 transgene (Fig. 10G). Depletion of *sens-2* function specifically in neurons via RNAi using *elav-*

GAL4 together with *repo-GAL80* had no effect on CNS structure or morphology (n=11/11; Fig.

10G), but depleting *sens-2* function specifically in glia using *repo-GAL4* recapitulated the

elongated nerve cord phenotype observed in *sens-2* mutant larvae (n=11/11; Fig. 10G). We note

that using *elav-GAL4* in the absence of *repo-GAL80* also resulted in elongated nerve cords

(n=11/12) due to the ability of *elav-GAL4* to drive significant gene expression in glia (Berger,

Renner et al. 2007). We observed similar results with the *sens-2-GAL4* line: RNAi-mediated

depletion of *sens-2* in all *sens-2* expressing cells elicited an elongated nerve cord (n=12/12), but

when *repo-GAL80* was used to block *sens-2* RNAi in glia, the phenotype disappeared, and nerve

cords appeared wild-type (n=11/11). Gene rescue experiments corroborated the above results:

Expression of a wild-type *sens-2* transgene under control of the *sens-2-GAL4* line in otherwise

sens-2 mutant larvae fully rescued the *sens-2* CNS phenotype (n=10/10), but when *repo-GAL80*

was used to block transgene expression specifically in glia, the *sens-2* elongated CNS phenotype

reappeared (n=10/10). We conclude that *sens-2* function is required solely in PNS perineurial and

perhaps subperineural glia to control CNS structure, and that loss of *sens-2* function in glial cells

alone is sufficient to yield the observed elongated nerve cord phenotype.

To assess the function of *sens-2* in different glial subtypes, we leveraged the GAL4/UAS system

and GAL4 lines specific for each glial subtype to drive *sens-2* expression and that of *Myr-GFP*,

which outlines cell morphology, in each glial subtype. We observed no gross change in cell

morphology upon *sens-2* misexpression in astrocyte-like, cortex, and ensheathing glia. Forced

expression of *sens-2* by two different perineurial-specific GAL4 lines, which also drive strong gene

expression in the gut, resulted in early larval lethality inhibiting our ability to assess the impact of

sens-2 misexpression in this glial subtype. Misexpression of *sens-2* in subperineural glia,

however, drove a clear change in cell morphology. Subperineural glia normally form a thin, flat

cell layer that fully encircles the circumference of the CNS and peripheral nerves and resides

immediately interior to the perineurial glial cell layer (Yildirim, Petri et al. 2019). Upon *sens-2*

misexpression in subperineural glia, these glial cells still fully encircle the CNS, but they now also

extend cell membranes into the interior of the CNS to fully or partially enwrap individual neurons

(arrows, Fig. 10H). *sens-2* misexpression in subperineural glia then modifies the behavior of this

glial cell type, bestowing on it the ability to enwrap neuronal cell bodies in addition to the entire

CNS, suggesting that *sens-2* alters the membrane properties of surface glia to facilitate their

ability to wrap peripheral nerves.

Our work on *sens-2* suggests that it acts as a genetic switch to distinguish the functional properties

of perineurial glia found In the PNS from those found in the CNS. A key difference between these

two tissues is their diameter – peripheral nerves are tiny in diameter relative to the much larger

CNS. In this context, the ability of forced *sens-2* expression to alter the behavior of subperineural

glia so that they inappropriately enwrap adjacent neuronal cell bodies highlights a profound impact

of *sens-2* expression on key functional properties of surface glia – their ability to enwrap (or not

enwrap) small diameter structures, such as cells or nerves. Our work did not clarify the molecular

basis through which *sens-2* dictates such functional properties. In the future it will be important to

identify the transcriptional targets of *sens-2* to clarify the exact mechanism through which it

governs the development and differentiation of perineurial glia in the PNS.

Summary: Prior work from many labs has highlighted the importance of interactions between the

basement membrane and glial cells in dictating CNS structure (Kim, Jeibmann et al. 2014, Meyer,

Schmidt and Klambt 2014, Skeath, Wilson et al. 2017). Initial results from our screen reinforce

these findings. *Tango1, C1GalTA, ppn,* and *pvf3* all appear to act on basement membrane

proteins, form components of the basement membrane, or regulate the survival or migration of

hemocytes, the bricklayers and tuckpointers of the basement membrane. Continued work on

these genes, especially *C1GalTA* and *ppn*, which likely act in the same pathway, holds the

promise of clarifying our understanding of basement membrane function and remodeling on tissue

structure. Conversely, *sens-2* and *ifc* act in glial cells to regulate CNS structure (this paper, Zhu

et al. 2024). We expect *Rme-8, CG9171*, and *Toll-2* also act in glia to regulate CNS shape, with

future work needed to confirm this prediction and to clarify if and how such factors interface with

the basement membrane to govern CNS morphology.

Materials and methods

<u>Genetic screen</u>: To identify mutations that disrupt larval CNS morphology, we performed a

standard, autosomal recessive forward genetic screen of the second chromosome using a

chromosome isogenic for the *M[3xP3-RFP.attP]* ϕC31 "landing pad" transgene inserted in

cytological location 51D. The *3xP3-RFP* construct in this transgene expresses RFP in most glia

and allows rapid visualization of CNS morphology in live larvae (Zhu, Cho et al. 2024). As outlined

in Figure 1, we mutagenized isogenic *M[3xP3-RFP.attP]* males with 25mM EMS for 8 hours,

allowed them to recover from EMS treatment overnight, and then mated them *en masse* to *CyO*

P[Tb^1-RFP]/wg^{Sp1} P[Hs-hid] virgin females, discarding mutagenized males on day 5. The *CyO*

P[Tb^1-RFP] chromosome carries the larval marker *Tubby* (*Tb*), facilitating the identification of

larvae that carry or do not carry this balancer based on larval body shape. The *wg^{Sp1} P[Hs-hid]*

chromosome carries the *hid* transgene under the control of the *hsp70* promoter, which induces

activation of the pro-apoptotic *hid* gene upon heatshock, killing all flies that carry this transgene.

17,790 F1 males of the *M[3xP3-RFP.attP]****/CyO P[Tb^1-RFP]* genotype, where "***" denotes the

mutagenized chromosome, were individually crossed to 3-5 *CyO P[Tb^1-RFP]/wg^{Sp1} P[Hs-hid]*

virgin females and allowed to mate for 7 days before adults were discarded. On days 8 and 9,

each vial was heat-shocked for 30-35 minutes at 37°C to ensure that only F2 progeny of the

following genotype survived: *M[3xP3-RFP.attP]****/CyO P[Tb^1-RFP]*. 12,211 of the 17,790 single

male crosses were successful; for each of these crosses, F2 progeny were sib-mated to expand

the stock and resulting F3 progeny were screened for larval-, pupal-, or semi-lethal phenotypes.

3180 lines displayed such a phenotype. For each of these lines, F4 larvae homozygous for the

mutagenized chromosome, easily identified by their lack of the *Tb* marker, were visually screened

for disrupted CNS morphology, e.g. an elongated CNS, under a fluorescent dissecting

microscope. 50 lines were identified that harbored second chromosomal mutations that when

homozygous disrupted the morphology of the larval CNS.

Complementation Analysis: The 50 mutations grouped into three phenotypic classes: those with

an elongated CNS (n=34), a herniated or mis-shaped CNS (n=15), or a wider CNS (n=1).

Exhaustive complementation crosses among lines within each group identified nine

complementation groups and nine "singleton" mutations. Crosses of each of these lines to second

chromosomal mutations known to disrupt CNS morphology, such as *Laminin B1 (LanB1)* and the

tightly linked *viking* and *Collagen Type IV alpha1 (Col4a1)* genes, identified nine alleles of *LanB1*

and one each of *viking* and, leaving eight complementation groups and six singletons.

Whole genome sequencing**:** At least three alleles per complementation group, all singleton

mutations, and the isogenic target chromosome were subjected to whole genome sequencing.

For each allele, 10-15 late third instar larvae homozygous for the relevant mutagenized *M[3xP3-*

RFP.attP]*** chromosome were collected, washed, and frozen. Genomic DNA extractions was

performed using the Qiagen DNeasy Blood & Tissue Kit and and Illumina Nextera Flex DNA

Library Prep Kit was used to prepare indexed next-generation sequencing libraries following the

manufacturer's protocol. Genomic DNA was then provided to GTAC (Washington University) for

whole genome sequencing at $\geq$30X coverage. Sequence reads were mapped

to *Drosophila* reference BDGP6 using NovoAlign (Novocraft Technologies). Sentieon software

was used to remove duplicate reads, realign reads around indels, recalibrate quality scores and

call variants. The Sentieon DNAscope tool was used to identify variants. Joint variant calls were

made using the mutant lines and a reference line. Variants were annotated using SnpEff and the

variants were filtered using SnpSift to select unique coding variants within previously determined

genomic intervals. Ultimately, this process identified nucleotide differences in coding regions and

splice sites and small deletions that differed between the mutagenized chromosome and the

isogenic target chromosome, which are likely EMS-induced mutations. For singletons, this

approach identified a list of putative EMS-induced mutations, one of which is likely the causative

lesion. For complementation groups, this approach identified the likely causative lesion for all

complementation groups, as only one gene in each complementation group harbored

independent EMS-induced mutations in its coding region in all sequenced alleles. When possible,

we confirmed correspondence between gene and mutant phenotype via complementation

crosses with appropriate deficiencies and gene-specific alleles and phenotypic analysis. All

putative causative lesions were confirmed via PCR-based methods and Sanger sequencing

(GeneWiz Inc.).

<u>Genetic mapping and Complementation Crosses:</u> To identify the causative lesion in singleton

alleles, we took two approaches. For three lines, we used complementation crosses against

deficiencies or gene-specific alleles that uncovered mutations likely to cause the associated CNS

phenotype to confirm correspondence between gene and mutant phenotype. This approach

identified mutations in *diaphanous*, *pvf3*, and *lethal giant larvae* as the causative to the CNS

phenotype. For the remaining three singletons, we used the approach of Zhai et al (Zhai,

Hiesinger et al. 2003) to map the causative lesion in each line on the genetic map relative to four

P[w+] element inserts located at genetic map positions 13, 52, 62, and 86 in the second

chromosome. Using this approach, we mapped one singleton to genetic map position 18-23 and

53-57 in the second chromosome; the results for the third singleton were inconclusive likely due

to the presence of two or more lethal mutations in the chromosome. Complementation crosses

against appropriate deficiencies and gene-specific alleles followed by phenotypic analysis

identified *Tango1* as the singleton on 2L and *worniu* as the singleton near genetic map position

53-57. The two putative causative lesions were confirmed by PCR-based methods and Sanger

sequencing.

<u>Transgene construction</u>: The *UAS-senseless-2* transgene was generated by amplifying

nucleotides 276-2529 of the *sens-2 cDNA*, FI 20031 (accession number BT33368). The resulting

PCR product was cloned into NotI and KpnI sites of pUAS-T. DNA was co-injected with helper

plasmid into embryos of the genotype w1118 by Rainbow Transgenic Flies, Inc.

Due to the large size of *ppn*, the UAS-Ppn[RG] transgene was constructed piecemeal through

PCR-based approaches amplified defined regions of partial cDNA clones and genomic DNA;

these individual regions were then stitched together via Gibson cloning. First, we used the

GH25513 cDNA clone, which contained a portion of the 5' coding region of Ppn (accession

number BT100225) to amplify nucleotides 1-2471 of the coding region of the Ppn[RG] transcript

starting with the ATG start codon in exon 1 and continuing into exon 6. Second, we used genomic

DNA from a strain of flies isogenic for a wild-type third chromosome to amplify nucleotides 2452-

5205 within exon 6 nucleotide 5162-5384 (exons 7) of the Ppn[RG] transcript. Third, we used the

partial 3' GH05059 cDNA clone (accession number AY060635) to amplify in separate reactions

nucleotides 5344-6602 (exons 8-9) and nucleotides 6556-8526 (exons 10 through 17, including

the ATT stop-codon) of the Ppn[RG] transcript. The PCR products were assembled via Gibson

cloning and inserted into the KpnI and XbaI sites of the phiC-based construct pJFRC28, which

was then injected into the P[CaryP] attp2 fly line (BDSC: 8622) with phiC integrase by Rainbow

Transgenic Flies, Inc.

Gene rescue and in vivo RNAi phenocopy assays

To restrict UAS-linked transgene expression specifically to glia, we used the *repoGAL4* driver

line. To restrict UAS-linked transgene expression specifically to neurons, we paired the *elavGAL4*

driver line, which activates transgene expression strongly in all neurons and moderately in glia,

with *repoGAL80*, which blocks GAL4-dependent activation in glia (Awasaki, Lai et al. 2008). Gene

rescue experiments were performed in the *sens-2-T2A-GAL4/sens-2^{js4}* background.

21
22
Allele nomenclature: Alleles were given with their final designation (e.g., js1, js2) after they were

placed in complementation groups. Within each complementation group alleles were named

based on the order in which they identified in the screen. The one singleton mutation was

designated *jsz4*.

Gene expression analysis: Gene expression analysis was performed essentially as described in

(Patel 1994). Briefly, the larval CNS was dissected in PBS, fixed in 3.7% formaldehyde for 35

minutes, and washed in PTx (1xPBS, 0.1% TritonX-100) five times over one hour prior to primary

antibody incubation. Fixed tissues was incubated in primary antibody with gentle rocking overnight

at room temperature, then washed five times in PTx over the course of an hour, incubated in the

appropriate secondary overnight for at least 4 hours to overnight at room temperature, and then

washed again in PTx at least five times over one hour. The CNS was then dissected and mounted

in PTx or in DPX mountant after dehydration via an ethanol series and clearing in xylenes

(Truman, Talbot et al. 1994). All imaging was performed on a Zeiss LSM-700 Confocal

Microscope, using Zen software. The following antibodies were used in the study: Deadpan

(1:2000, (Skeath, Wilson et al. 2017)); rat monoclonal antibody 7E8A10 (ELAV; 1:200; (O'Neill,

Rebay et al. 1994)); mouse monoclonal antibody 8D12 (REPO; 1:100) (Alfonso and Jones 2002);

rabbit anti-Sens-2 (this paper; 1:500); rabbit anti-Ppn (this paper; 1:250); goat Anti-GFP Dylight

TM 488 Conjugated, preadsorbed, (Rockland; #600-141-215). Secondary antibodies were

obtained from the following sources. The Alexa Fluor Plus 488 secondary antibodies of

appropriate species specificity were obtained from ThermoFisher and used at a dilution of 1:400:

e.g., Donkey anti-Rat IgG Alexa Fluor™ Plus 488; catalog number Cat # A-21208. The Cy5

secondary antibodies of appropriate species specificity were obtained from Jackson

Immunoresearch and used at a dilution of 1:400: e.g., Cy5 Donkey Anti-Rat IgG, #712-175-153.

25
Antibody generation

To generate the *Senseless-2* antibody, DNA encoding amino acids 1-199 of Senseless-2 was

inserted into pET-29a (Novagen) for protein expression and purification. Protein-specific antibody

responses were mounted in rabbits (Pocono Rabbit Farm and Laboratory, PA, USA) and the

resulting sera was used at a 1:500-1:1000 dilution. As all senseless-2 mutations arise C-terminal

to the epitopes against which the antibody was generated, we confirmed specificity of this

antibody to senseless-2 by driving UAS-senseless-2 expression in subperineural glia within the

ventral nerve cord, which normally do not express *senseless-2*, and detecting high levels of

Senseless-2 protein in these cells (Fig. S1).

Papilin antibody generation: YenZym (CA, USA) was used as a commercial source to generate

affinity purified antibodies against two distinct synthetic peptides that corresponded to amino acids

27-47 (RFPGLRQKRQYGANMYLPEC) and 2670-2691 (TRPVTQRPSYPYRPTRPAYVPE) of

Ppn-PG. Briefly, each peptide was conjugated to KLH, used as an immunogen in rabbits to

generate a peptide-specific antibody response, and antibodies specific to the peptide were affinity

purified. The two affinity purified antibodies were combined and used at a dilution of 1:250-1:500

for immunofluorescence analysis.

<u>Generation of senseless-2 CRIMIC T2A-GAL4 line</u>

To generate sens-2-GAL4-DBD, we used a modified version of the strategy developed by Kanca

et al. (Kanca, Zirin et al. 2019). We used the Genewiz company to synthesize a DNA fragment

into the EcoRV site of the pUC-GW-Kan vector. This fragment is made of the left and right

homology arms (HA) which are immediately adjacent to the cut site and restriction enzyme sites

(SacI- KpnI) between these arms. We then directionally cloned the attp-FRT-splitGAL4-FRT-attp

fragment (see below) into the middle of left and right HAs using the SacI and KpnI sites. We used

the genome sequence of the injected flies (vasa-cas9, BDSC-51324) for design.

HA flanking sequences:

Left HA: 5'cgtgtgtgagagaga 3'aacggtcttttccct;

Right HA: 5'gggtggggcagcgcc 3'tatctatcatagata

SacI-attp-FRT-splitGAL4-FRT-attp-Kpn1 fragment:

We used the Gibson cloning method to clone three fragments into pBS-KS digested with SacI

and KpnI. Primer pairs and templates shown below: Note we also included ECoRI and EcoRV

sites for replacing the trojan exon between attpFRT sites as a back-up strategy when needed.

1. *SacI*-attp-FRT from pM14 (Kanca, Zirin et al. 2019):

8   a. F actcactatagggcgaattgGAGCTC*acggacacaccgaag*

9   b. R *caagtcgccatgttggatcgac*

2. Split-GAL4 from Trojan-AD/DBD (Diao, Ironfield et al. 2015):

a. F cta*gaaagtataggaacttc*GAATTC**agtcgatccaacatggcgacttg**

b. R cttt*ctagagaataggaacttc*GATATC**aaacgagtttttaagcaaactcactcc**

3. Kpn1-attp-FRT from pM14 (Kanca, Zirin et al. 2019):

a. F **ggagtgagtttgcttaaaaactcgttt**GATATCgaag*ttcctattctctagaaag*

b. R cactaaagggaacaaaagctgGGTACCgtac*gacggacacaccgaag*

Corresponding sequences from pBS-KS are underlined, pM14 are in italics, and Trojan AD/DBD

are in bold; restriction enzyme sites are in all caps.

Guide RNAs were identified with CRISPR target Finder (Gratz, Ukken et al. 2014) with maximum

stringency and minimal off-target effects. We used pCFD4 vector (Port, Chen et al. 2014) to clone

sens-2 specific guide and donor linearizing guide RNAs via a PCR intermediate with the following

primers:

sens-2 guide RNA: attttaacttgctatttctagctctaaaacCCCAACGGTCTTTTCCCTGC

gacgttaaattgaaaataggtc

linearizing guide RNA: tatataggaaagatatccgggtgaacttcGTAGTACGATCATAACAACG

gttttagagctagaaatagcaag

All constructs were injected into *vasa-cas9* (BDSC #51324), which were then crossed to *Tubulin-*

GAL4-AD, UAS-TdTomato/CyO and scored for TdTomato expression to identify positive lines.

Verification of targeting was confirmed via PCR-based sequencing methods. After we generated

the *sens-2-GAL4-DBD* line, we used the strategy described in Diao et al., (Diao, Ironfield et al.

2015) to replace the split-GAL4 insert with a T2A-GAL4 and then conducted all experiments with

the sens-2-T2A-GAL4 line, termed *sens-2-GAL4*.

The *papilin*-T2A-GAL4 line was generated from the *ppn^{MI03189}* insert following the genetic cross

scheme outlined in Diao et al., 2015 (Diao, Ironfield et al. 2015).

Fly Stocks used:

Genotype	Source	Notes
M{3xP3-RFP.attP}ZH-51D	Derived from BDSC #24483	Wildtype. Control for 3xP3 background.
P[w+] lines used to map genes on the genetic map		
w[1118]; P{y[+mDint2] w[BR.E.BR]=SUPor-P}KG07698/CyO (Genetic map position: 2-13)	BDSC #15116	
y[1] w[67c23]; P{y[+mDint2] w[BR.E.BR]=SUPor-P}grp[KG08033] (Genetic map position: 2-52)	BDSC #14931	
y[1] w[67c23]; P{y[+mDint2] w[BR.E.BR]=SUPor-P}whd[KG01596] (Genetic map position: 2-62)	BDSC #13731	
y[1] w[67c23]; P{y[+mDint2] w[BR.E.BR]=SUPor-P}KG07930 (Genetic map position: 2-86)	BDSC #14672	
Lines used for complementation tests		
LanB1^{KG03456}/CyO	BDSC #13907	
Df(2L)BSC172/CyO	BDSC #9605	Small deficiency that removes *viking* and Col4a1

dia[5]/CyO	BDSC #9138	Failed to complement *dia[js1]*
Df(2L)BSC6/CyO	BDSC #6338	Failed to complement *Tango1[js1]*
Df(2L)BSC188/CyO	BDSC #9615	Failed to complement *Tango1[js1]*
l(2)lgl⁴/CyO	BDSC #36289	Failed to complement *l(2)lgl[js1]*
Df(2L)ED50001/CyO	BDSC #24626	Failed to complement *l(2)lgl[js1]*
worniu¹/CyO	BDSC #3155	Failed to complement *wor[js1]*
worniu²/CyO	BDSC #25170	Failed to complement *wor[js1]*
Df(2L)ΔPvf2-3/CyO	Parsons and Foley, 2013	Failed to complement *Pvf3[js1]*
Pvf3[MI04168]/CyO	BDSC #37270	Failed to complement *Pvf3[js1]*
Pvf3[MI15271]/CyO	BDSC #61008	Failed to complement *Pvf3[js1]*
P{EP}PpnG4259/CyO	BDSC #31782	
ppn[MI03189]/CyO	BDSC #36216	
w[1118]; P{y[+t7.7] w[+mC]=GMR78D01-GAL4}attP2	BDSC #47014	Drives GAL4 in fat body
w, hs-flp		
P{w[+mC]=GAL4-Act5C(FRT.CD2).P}S, P{w[+mC]=UAS-RFP.W}3, P{w[+mC]=UAS-Ppn-RG}/TM6, Tb[1]	Derived from BDSC #30558	
y[1] sc[*] v[1] sev[21]; P{y[+t7.7] v[+t1.8]=TRiP.HMS01394}attP2	BDSC #34984	*UAS-sens-2-RNAi*
PBac{sens-2-GFP.FPTB}VK00031	BDSC #93096	*sens-2-GFP*
w[1118]; P{y[+t7.7] w[+mC]=GMR54H02-GAL4}attP2	BDSC #45784	Cortex glia GMR-GAL4
w[1118]; P{y[+t7.7] w[+mC]=GMR86E01-GAL4}attP2	BDSC #45914	Astrocyte-like glia GMR-GAL4
w[1118]; P{y[+t7.7] w[+mC]=GMR56F03-GAL4}attP2	BDSC #39157	Ensheathing glia GMR-GAL4
w[1118]; P{y[+t7.7] w[+mC]=GMR54C07-GAL4}attP2	BDSC #50472	Subperineurial glia GMR-GAL4
w[1118]; P{y[+t7.7] w[+mC]=GMR85G01-GAL4}attP2	BDSC #40436	Perineurial glia GMR-GAL4
P{w[+mC]=GAL4-repo/TM6 Tb	BDSC #7415	Pan-glial driver

P{w[+mC]=GAL4-elav[C155]}	BDSC #458	Pan-neuronal driver; also expressed in glia
P{w[+mC]=GAL4-elav[C155]}; Repo-GAL80/TM6, Tb	Skeath et al., 2017	Pan-neuronal driver
TI[CRIMIC.TG4.1}Rme-8^{CR00765}-TG4.1/SM6a	BDSC #80650	T2A-GAL4 insert in *Rme-8*
P{y[+t7.7] v[+t1.8]=UAS-TransTimer.v+}attP2	BDSC #93411	Contains nuclear targeted UAS-TagRFP transgene
sens-2-GAL4; CyO Tb; repo-GAL4/TM6 Tb	This paper	
sens-2^{is4}/CyO Tb; UAS-sens-2	This paper	

1
2

Data Availability Statement

All data necessary for confirming the conclusions of this manuscript are represented within the

article, its tables, figures, and supplementary information. All fly stocks are available upon

request.

Acknowledgements

We thank the Iowa Developmental Studies Hybridoma Bank for antibodies, and the Bloomington

Stock Center for fly stocks. We thank the Genome Technology Access Center (GTAC) at

Washington University for next-generation sequencing.

Conflict of Interest: The authors declare no competing interests.

12
13 **Funding:** This work was supported by grants from the National Institutes of Health to J.B.S.
14 (NS036570) and to H.L. (NS122903).
15

References:

Alfonso, T. B. and B. W. Jones (2002). "gcm2 promotes glial cell differentiation and is required with glial cells missing for macrophage development in Drosophila." <u>Dev Biol</u> **248**(2): 369-383.

Apte, S. S. (2009). "A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms." <u>J Biol Chem</u> **284**(46): 31493-31497.

Ashraf, S. I., A. Ganguly, J. Roote and Y. T. Ip (2004). "Worniu, a Snail family zinc-finger protein, is required for brain development in Drosophila." <u>Dev Dyn</u> **231**(2): 379-386.

Awasaki, T., S. L. Lai, K. Ito and T. Lee (2008). "Organization and postembryonic development of glial cells in the adult central brain of Drosophila." <u>J Neurosci</u> **28**(51): 13742-13753.

Berger, C., S. Renner, K. Luer and G. M. Technau (2007). "The commonly used marker ELAV is transiently expressed in neuroblasts and glial cells in the Drosophila embryonic CNS." <u>Dev Dyn</u> **236**(12): 3562-3568.

Bigotti, M. G. and A. Brancaccio (2021). "High degree of conservation of the enzymes synthesizing the laminin-binding glycoepitope of alpha-dystroglycan." <u>Open Biol</u> **11**(9): 210104.

Campbell, A. G., L. I. Fessler, T. Salo and J. H. Fessler (1987). "Papilin: a Drosophila proteoglycan-like sulfated glycoprotein from basement membranes." <u>J Biol Chem</u> **262**(36): 17605-17612.

Castrillon, D. H. and S. A. Wasserman (1994). "Diaphanous is required for cytokinesis in Drosophila and shares domains of similarity with the products of the limb deformity gene." <u>Development</u> **120**(12): 3367-3377.

Dai, J., B. Estrada, S. Jacobs, B. J. Sanchez-Sanchez, J. Tang, M. Ma, P. Magadan-Corpas, J. C. Pastor-Pareja and M. D. Martin-Bermudo (2018). "Dissection of Nidogen function in Drosophila reveals tissue-specific mechanisms of basement membrane assembly." <u>PLoS Genet</u> **14**(9): e1007483.

Diao, F., H. Ironfield, H. Luan, F. Diao, W. C. Shropshire, J. Ewer, E. Marr, C. J. Potter, M. Landgraf and B. H. White (2015). "Plug-and-play genetic access to drosophila cell types using exchangeable exon cassettes." <u>Cell Rep</u> **10**(8): 1410-1421.

Gateff, E. (1994). "Tumor-suppressor genes, hematopoietic malignancies and other hematopoietic disorders of Drosophila melanogaster." <u>Ann N Y Acad Sci</u> **712**: 260-279.

Gateff, E. and H. A. Schneiderman (1974). "Developmental capacities of benign and malignant neoplasms ofDrosophila." <u>Wilhelm Roux Arch Entwickl Mech Org</u> **176**(1): 23-65.

Gomez-Lamarca, M., L. A. Snowdon, E. Seib, T. Klein and S. Bray (2015). "Rme-8 depletion perturbs Notch recycling and predisposes to pathogenic signaling." <u>J Cell Biol</u> **210**(3): 517.

Gratz, S. J., F. P. Ukken, C. D. Rubinstein, G. Thiede, L. K. Donohue, A. M. Cummings and K. M. O'Connor-Giles (2014). "Highly specific and efficient CRISPR/Cas9-catalyzed homology-directed repair in Drosophila." <u>Genetics</u> **196**(4): 961-971.

Hannun, Y. A. and L. M. Obeid (2018). "Sphingolipids and their metabolism in physiology and disease." <u>Nat Rev Mol Cell Biol</u> **19**(3): 175-191.

He, L., R. Binari, J. Huang, J. Falo-Sanjuan and N. Perrimon (2019). "In vivo study of gene expression with an enhanced dual-color fluorescent transcriptional timer." <u>Elife</u> **8**.

Hermanstyne, T. O., L. Johnson, K. M. Wylie and J. B. Skeath (2022). "Helping others enhances graduate student wellness and mental health." <u>Nat Biotechnol</u> **40**(4): 618-619.

Isabella, A. J. and S. Horne-Badovinac (2015). "Building from the Ground up: Basement Membranes in Drosophila Development." Curr Top Membr **76**: 305-336.

Jung, W. H., C. C. Liu, Y. L. Yu, Y. C. Chang, W. Y. Lien, H. C. Chao, S. Y. Huang, C. H. Kuo, H. C. Ho and C. C. Chan (2017). "Lipophagy prevents activity-dependent neurodegeneration due to dihydroceramide accumulation in vivo." EMBO Rep **18**(7): 1150-1165.

Kanca, O., J. Zirin, J. Garcia-Marques, S. M. Knight, D. Yang-Zhou, G. Amador, H. Chung, Z. Zuo, L. Ma, Y. He, W. W. Lin, Y. Fang, M. Ge, S. Yamamoto, K. L. Schulze, Y. Hu, A. C. Spradling, S. E. Mohr, N. Perrimon and H. J. Bellen (2019). "An efficient CRISPR-based strategy to insert small and large fragments of DNA using short homology arms." Elife **8**.

Karkali, K., P. Tiwari, A. Singh, S. Tlili, I. Jorba, D. Navajas, J. J. Munoz, T. E. Saunders and E. Martin-Blanco (2022). "Condensation of the Drosophila nerve cord is oscillatory and depends on coordinated mechanical interactions." Dev Cell **57**(7): 867-882 e865.

Keeley, D. P., E. Hastie, R. Jayadev, L. C. Kelley, Q. Chi, S. G. Payne, J. L. Jeger, B. D. Hoffman and D. R. Sherwood (2020). "Comprehensive Endogenous Tagging of Basement Membrane Components Reveals Dynamic Movement within the Matrix Scaffolding." Dev Cell **54**(1): 60-74 e67.

Kim, S. N., A. Jeibmann, K. Halama, H. T. Witte, M. Walte, T. Matzat, H. Schillers, C. Faber, V. Senner, W. Paulus and C. Klambt (2014). "ECM stiffness regulates glial migration in Drosophila and mammalian glioma models." Development **141**(16): 3233-3242.

Kramerova, I. A., N. Kawaguchi, L. I. Fessler, R. E. Nelson, Y. Chen, A. A. Kramerov, M. Kusche-Gullberg, J. M. Kramer, B. D. Ackley, A. L. Sieron, D. J. Prockop and J. H. Fessler (2000). "Papilin in development; a pericellular protein with a homology to the ADAMTS metalloproteinases." Development **127**(24): 5475-5485.

Kudron, M. M., A. Victorsen, L. Gevirtzman, L. W. Hillier, W. W. Fisher, D. Vafeados, M. Kirkey, A. S. Hammonds, J. Gersch, H. Ammouri, M. L. Wall, J. Moran, D. Steffen, M. Szynkarek, S. Seabrook-Sturgis, N. Jameel, M. Kadaba, J. Patton, R. Terrell, M. Corson, T. J. Durham, S. Park, S. Samanta, M. Han, J. Xu, K. K. Yan, S. E. Celniker, K. P. White, L. Ma, M. Gerstein, V. Reinke and R. H. Waterston (2018). "The ModERN Resource: Genome-Wide Binding Profiles for Hundreds of Drosophila and Caenorhabditis elegans Transcription Factors." Genetics **208**(3): 937-949.

Lee, P. T., J. Zirin, O. Kanca, W. W. Lin, K. L. Schulze, D. Li-Kroeger, R. Tao, C. Devereaux, Y. Hu, V. Chung, Y. Fang, Y. He, H. Pan, M. Ge, Z. Zuo, B. E. Housden, S. E. Mohr, S. Yamamoto, R. W. Levis, A. C. Spradling, N. Perrimon and H. J. Bellen (2018). "A gene-specific T2A-GAL4 library for Drosophila." Elife **7**.

Li, G., M. G. Forero, J. S. Wentzell, I. Durmus, R. Wolf, N. C. Anthoney, M. Parker, R. Jiang, J. Hasenauer, N. J. Strausfeld, M. Heisenberg and A. Hidalgo (2020). "A Toll-receptor map underlies structural brain plasticity." Elife **9**.

Lin, Y. R., B. V. Reddy and K. D. Irvine (2008). "Requirement for a core 1 galactosyltransferase in the Drosophila nervous system." Dev Dyn **237**(12): 3703-3714.

Malhotra, V. and P. Erlmann (2011). "Protein export at the ER: loading big collagens into COPII carriers." EMBO J **30**(17): 3475-3480.

Meyer, S., I. Schmidt and C. Klambt (2014). "Glia ECM interactions are required to shape the Drosophila nervous system." Mech Dev **133**: 105-116.

Miller, C. M., N. Liu, A. Page-McCaw and H. T. Broihier (2011). "Drosophila MMP2 regulates the matrix molecule faulty attraction (Frac) to promote motor axon targeting in Drosophila." J Neurosci **31**(14): 5335-5347.

Morin, X., R. Daneman, M. Zavortink and W. Chia (2001). "A protein trap strategy to detect GFP-tagged proteins expressed from their endogenous loci in Drosophila." Proc Natl Acad Sci U S A **98**(26): 15050-15055.

Norris, A., C. T. McManus, S. Wang, R. Ying and B. D. Grant (2022). "Mutagenesis and structural modeling implicate RME-8 IWN domains as conformational control points." PLoS Genet **18**(10): e1010296.

O'Neill, E. M., I. Rebay, R. Tjian and G. M. Rubin (1994). "The activities of two Ets-related transcription factors required for Drosophila eye development are modulated by the Ras/MAPK pathway." Cell **78**(1): 137-147.

Olofsson, B. and D. T. Page (2005). "Condensation of the central nervous system in embryonic Drosophila is inhibited by blocking hemocyte migration or neural activity." Dev Biol **279**(1): 233-243.

Page-McCaw, A., J. Serano, J. M. Sante and G. M. Rubin (2003). "Drosophila matrix metalloproteinases are required for tissue remodeling, but not embryonic development." Dev Cell **4**(1): 95-106.

Parsons, B. and E. Foley (2013). "The Drosophila platelet-derived growth factor and vascular endothelial growth factor-receptor related (Pvr) protein ligands Pvf2 and Pvf3 control hemocyte viability and invasive migration." J Biol Chem **288**(28): 20173-20183.

Pastor-Pareja, J. C. and T. Xu (2011). "Shaping cells and organs in Drosophila by opposing roles of fat body-secreted Collagen IV and perlecan." Dev Cell **21**(2): 245-256.

Patel, N. H. (1994). "Imaging neuronal subsets and other cell types in whole-mount Drosophila embryos and larvae using antibody probes." Methods Cell Biol **44**: 445-487.

Petley-Ragan, L. M., E. L. Ardiel, C. H. Rankin and V. J. Auld (2016). "Accumulation of Laminin Monomers in Drosophila Glia Leads to Glial Endoplasmic Reticulum Stress and Disrupted Larval Locomotion." J Neurosci **36**(4): 1151-1164.

Port, F., H. M. Chen, T. Lee and S. L. Bullock (2014). "Optimized CRISPR/Cas tools for efficient germline and somatic genome engineering in Drosophila." Proc Natl Acad Sci U S A **111**(29): E2967-2976.

Praissman, J. L., D. H. Live, S. Wang, A. Ramiah, Z. S. Chinoy, G. J. Boons, K. W. Moremen and L. Wells (2014). "B4GAT1 is the priming enzyme for the LARGE-dependent functional glycosylation of alpha-dystroglycan." Elife **3**.

Rodriguez, A., H. Oliver, H. Zou, P. Chen, X. Wang and J. M. Abrams (1999). "Dark is a Drosophila homologue of Apaf-1/CED-4 and functions in an evolutionarily conserved death pathway." Nat Cell Biol **1**(5): 272-279.

Rodriguez-Manzaneque, J. C., R. Fernandez-Rodriguez, F. J. Rodriguez-Baena and M. L. Iruela-Arispe (2015). "ADAMTS proteases in vascular biology." Matrix Biol **44-46**: 38-45.

Saito, K., M. Chen, F. Bard, S. Chen, H. Zhou, D. Woodley, R. Polischuk, R. Schekman and V. Malhotra (2009). "TANGO1 facilitates cargo loading at endoplasmic reticulum exit sites." Cell **136**(5): 891-902.

Skeath, J. B., B. A. Wilson, S. E. Romero, M. J. Snee, Y. Zhu and H. Lacin (2017). "The extracellular metalloprotease AdamTS-A anchors neural lineages in place within and preserves the architecture of the central nervous system." Development **144**(17): 3102-3113.

Stork, T., D. Engelen, A. Krudewig, M. Silies, R. J. Bainton and C. Klambt (2008). "Organization and function of the blood-brain barrier in Drosophila." J Neurosci **28**(3): 587-597.

Truman, J. W., W. S. Talbot, S. E. Fahrbach and D. S. Hogness (1994). "Ecdysone receptor
expression in the CNS correlates with stage-specific responses to ecdysteroids during Drosophila
and Manduca development." Development **120**(1): 219-234.
Wilson, D. G., K. Phamluong, L. Li, M. Sun, T. C. Cao, P. S. Liu, Z. Modrusan, W. N. Sandoval,
L. Rangell, R. A. Carano, A. S. Peterson and M. J. Solloway (2011). "Global defects in collagen
secretion in a Mia3/TANGO1 knockout mouse." J Cell Biol **193**(5): 935-951.
Yildirim, K., J. Petri, R. Kottmeier and C. Klambt (2019). "Drosophila glia: Few cell types and
many conserved functions." Glia **67**(1): 5-26.
Yoshida-Moriguchi, T., L. Yu, S. H. Stalnaker, S. Davis, S. Kunz, M. Madson, M. B. Oldstone,
H. Schachter, L. Wells and K. P. Campbell (2010). "O-mannosyl phosphorylation of alpha-
dystroglycan is required for laminin binding." Science **327**(5961): 88-92.
Yurchenco, P. D. (2011). "Basement membranes: cell scaffoldings and signaling platforms."
Cold Spring Harb Perspect Biol **3**(2).
Zhai, R. G., P. R. Hiesinger, T. W. Koh, P. Verstreken, K. L. Schulze, Y. Cao, H. Jafar-Nejad, K.
K. Norga, H. Pan, V. Bayat, M. P. Greenbaum and H. J. Bellen (2003). "Mapping Drosophila
mutations with molecularly defined P element insertions." Proc Natl Acad Sci U S A **100**(19):
10860-10865.
Zhang, Y., B. Grant and D. Hirsh (2001). "RME-8, a conserved J-domain protein, is required for
endocytosis in Caenorhabditis elegans." Mol Biol Cell **12**(7): 2011-2021.
Zhu, Y., K. Cho, H. Lacin, Y. Zhu, J. DiPaola, B. A. Wilson, G. J. Patti and J. B. Skeath (2024).
"Dihydroceramide desaturase governs endoplasmic reticulum and lipid droplet homeostasis to
promote glial function in the nervous system." BioRxiv.
23
24

Figure Legends

Figure 1: Diagram of the genetic cross scheme used to execute the forward genetic screen.

Figure 2: Representative examples of CNS mutant phenotypes identified in the genetic screen.

Ventral views of wild-type and mutant late third instar larvae of the indicated genotype showing

3xP3 RFP staining in greyscale to highlight CNS morphology. Anterior is up; scale bar is 500µm**.**

Figure 3: Mutations in *diaphanous* increase the width of the CNS. A) Schematic of Diaphanous

protein with location and nature of the *dia^{js1}* allele. B) Ventral views of wild-type or *dia^{js1}* mutant

late-third instar larvae with 3xP3 RFP expression (greyscale) highlighting the CNS. Anterior is up;

scale bar is 250 µm. C-G) Ventral views of dissected CNS (C,D) or high magnification view of the

brain (E, F) from wild-type and *dia^{js1}* mutant late-third instar larvae labeled for neuroblasts with

Deadpan (Dpn; green in C, D, and grey in E, F) and for neurons with ELAV (magenta in C, D).

Arrows highly enlarged neuroblasts. Anterior is up; scale bar is 100 Anterior is 100 µm in panels

D and E and 50 µm in F and G.

Figure 4: Loss of *Toll-2* function results in a misshapen CNS. A) Schematic of Toll-2 protein with

location and nature of identified *Toll-2* alleles. B-E) Ventral views of wild-type or *Toll-2* mutant

late-third instar larvae in which 3xP3 RFP expression (greyscale) highlights the CNS. Arrows

highlight hernias, bulges, or dysmorphology in the CNS. Anterior is up; scale bar is 500µm. F-I)

Ventral views of dissected CNS of wild-type (F) and *Toll-2* mutant (G-I) late-third instar larvae

labeled for neuroblasts with Deadpan (Dpn; green) and neurons with ELAV (magenta). Arrows

point to areas of the CNS that display dysmorphology. Anterior is up; scale bar is 200 µm.

Figure 5: Loss of *Rme-8* function promotes CNS elongation. A) Schematic of Rme-8 protein

showing the location of the lipid binding, IWN repeat, and DnaJ domains as well as the location

and nature of the three identified *Rme-8* alleles. B-E) Ventral views of wild-type or *Rme-8* mutant late-third instar larvae in which 3xP3 RFP expression (greyscale) highlights the CNS. Anterior is up; scale bar is 500μm. F-G) Ventral views of dissected CNS of wild-type (F) and *Rme-8* mutant (G) late-third instar larvae labeled for neuroblasts with Dpn (green) and neurons with ELAV (magenta). Anterior is up; scale bar is 200 μm.

Figure 6: Loss of *Pvf-3* function greatly increases the length of the ventral nerve cord. A) Schematic of Pvf-3 protein with location and nature of the *Pvf-3^{js1}* allele. B-E) Ventral views of wild-type or *Pvf-3^{js1}* mutant late-third instar larvae in which 3xP3 RFP expression (greyscale) highlights the CNS. Anterior is up; scale bar is 500μm. D, E) Ventral views of dissected CNS of wild-type (F) and *Pvf-3^{js1}* mutant (G-I) late-third instar larvae labeled for neuroblasts with Deadpan (Dpn; green) and for neurons with ELAV (magenta). Anterior is up; scale bar is 200 μm**.**

Figure 7: Loss of *CG9171* drives CNS elongation. A) Schematic of CG9171 protein with location and nature of the four identified *CG9171* alleles. B-F) Ventral views of wild-type or *CG9171* mutant late-third instar larvae in which 3xP3 RFP expression (greyscale) highlights the CNS. Anterior is up; scale bar is 500μm. G-H) Ventral views of dissected CNS of wild-type (G) and *CG9171* mutant (H) late-third instar larvae labeled for neuroblasts with Dpn (green) and neurons with ELAV (magenta). Anterior is up; scale bar is 200 μm**.**

Figure 8: Loss of *dC1GalTA* function promotes CNS elongation. A) Schematic of C1GalTA protein with location of its Fringe-like glycosyltransferase domain and the nature of the two identified alleles. B-C) Ventral views of wild-type or *C1GalTA^{js1/js2}* mutant late-third instar larvae in which 3xP3 RFP expression (greyscale) highlights the CNS. Anterior is up; scale bar is 500μm. D, E) Ventral views of dissected CNS of wild-type (F) and *C1GalTA^{js1/js2}* mutant (G-I) late-third

instar larvae labeled for neuroblasts with Deadpan (Dpn; green) and for neurons with ELAV

(magenta). Anterior is up; scale bar is 100 μm**.**

Figure 9: *papilin* regulates CNS structure and is sufficient to drive accumulation of Vkg-GFP in

the fat body. A-B) Ventral view of CNS of wild-type (A) and *ppn^MI03189^* mutant late third instar larvae

labeled for ELAV (grey scale). Anterior is up; scale bar is 100 μm. (C-D) Stage 15-16 embryos

labeled for Ppn (grey, C; red, D-D') and Collagen 4a1 (green, D). Anterior is to the left; scale bars

are 50 μm. Arrowheads in D-D' point to Ppn⁺ hemocytes immediately adjacent to the fat body. E-

G) vkg-GFP localization (grey in E, F; green in G) in wild-type fat body (E), fat body in which

Ppn[RG] is expressed in all fat body cells (F), and fat body in which small cell clones, marked in

magenta, ectopically express Papilin protein (G). Scale bar is 50 μm.

Figure 10: *sens-2* acts in peripheral glia to regulate CNS structure. A) Schematic of Sens-2

protein with location and nature of the four identified *sens-2* mutations. B) Ventral views of late-

third instar larvae of indicated genotype showing 3xP3 RFP expression (greyscale) in the CNS

and nerves. Anterior is up; scale bar is 500μm. C) Ventral views of photomontages of late third

instar larvae of the indicated genotypes labeled for neuroblasts with Deadpan (Dpn; green) and

for neurons with ELAV (magenta). Anterior is up; scale bar is 200 μm. D-F) Ventral views of low

(D) and high magnification (E,F) images of the CNS (D,E) and peripheral nerves (F) of late third

instar larvae labeled for *sens-2-GFP* (green and greyscale) to mark *sens-2* expressing cells and

REPO (magenta) to mark glia. Arrows in C,D identify peripheral glia that express *sens-2-GFP*;

arrowheads identify central glia that lack GFP expression. Arrowhead in E marks *sens-2-GFP*-

negative wrapping glia in peripheral nerve. G) Ventral views of the dissected CNS from late third

instar larvae of indicated genotype labeled for ELAV (greyscale) to mark neurons and highlight

the structure of the CNS. Anterior is up; scale bar is 200 μm. H) Ventral view and Y-Z and X-Z

projection views of late third instar larvae of indicated genotype labeled for Myr-GFP

(green/greyscale) and ELAV to label neurons (magenta). Arrows point to Myr-GFP+ membrane

invaginations that enwrap neurons. Anterior is up; scale bar is 20 µm.

Table 1) Molecular nature, phenotypic class, and causative lesions of identified genes

Gene (alleles)	CNS Phenotype	Causative mutations	Protein Function
LanB1 (9)	Highly Elongated	Not sequenced	Basement membrane Protein
viking (1)	Elongated	vkg^{js1}: G585D	Basement membrane Protein
Collagen 4a1 (1)	Elongated	$Col4a1^{js1}$: G1702S	Basement membrane Protein
diaphanous (1)	Wide	dia^{js1}: A51fs	Dia-class Formin
Toll-2 (18-wheeler) (3)	Misshapen	$18w^{js1}$: N293H $18w^{js2}$: Q477* $18w^{js3}$: Q90*	Toll-like receptor family (Toll-2)
dark (11)	Misshapen (mild)	$Dark^{js1-js3}$: Identical 370 bp that deletes amino acids 830-952 and introduces frameshift after the deletion $Dark^{js4-11}$ Not Sequenced	Essential component of apoptosome
jsZ4 (1)	Misshapen	Unknown	Unknown
Brain tumor (3)	Elongated	$brat^{js1}$: 114 bp deletion that removes start codon $brat^{js2}$: W688* $brat^{js3}$: Q294*,	Tumor suppressor
Lethal(2) giant larvae (1)	Elongated	lgl^{js1}: T331fs	Tumor suppressor
worniu (1)	Elongated	wor^{js1}: L117*	Zinc finger C2H2 transcription factor
Tango1 (1)	Elongated	$Tango1^{js1}$: T60I	Protein secretion
Rme-8 (3)	Elongated	Rme-8^{js1}: W837*, Rme-8^{js2}: P1200S Rme-8^{js3}: K1779-Splice Acceptor mutation (c.5337-1C>T, intron 15)	DnaJ domain containing Hsp40 family protein involved in receptor-mediated endocytosis
Pvf3 (1)	Highly Elongated	$Pvf3^{js1}$: A451-Splice Donor mutation; (c.1351+1C>T, intron 2)	PDGF- and VEGF-related ligand for Pvr receptor
CG9171 (4)	Highly Elongated	$CG9171^{js1}$: I240N $CG9171^{js2}$: T214I $CG9171^{js3}$: R336-Splice Donor mutation (c.1127+1C>T, intron 3) $CG9171^{js4}$: E489V	Glucuronosyltransferase
dC1GalTA (2)	Highly Elongated	$dC1GalTA^{js1}$: K298* $dC1GalTA^{js2}$: M191K	Core 1 Galactosyltransferase A
infertile crescent (3)	Highly Elongated	ifc^{js1}: V276D ifc^{js2}: G257S ifc^{js3}: W240*	Dihydroceramide desaturase
senseless-2 (4)	Highly Elongated	$sens$-2^{js1}: R590L $sens$-2^{js2}: G421-Splice Acceptor mutation (c. 1263-1G>A, intron 2) $sens$-2^{js3}: C622Y $sens$-2^{js4}: R258fs	Zinc finger C2H2 transcription factor

Figure 1:

Figure 2:

Figure 3:

A51fs

| GTPase-binding domain | Formin homology domain 3 | Formin homology domain 2 |

wild-type   dia^{js1}

wild-type   dia^{js1}

A   B

C   D

E   F

Figure 4:

Figure 5:

Figure 6:

Figure 7:

Figure 8:

Figure 9:

Figure 10: